Recognizing Keytruda Allergy Symptoms
Keytruda (pembrolizumab), an immunotherapy for cancers like melanoma and lung cancer, can trigger allergic reactions or immune-related adverse events. Initial signs include skin rash, itching, hives, swelling (face, lips, tongue), shortness of breath, dizziness, or rapid heartbeat during or soon after infusion. Severe cases mimic anaphylaxis with throat tightening or low blood pressure. These overlap with infusion reactions, which occur in up to 15-20% of patients, often within minutes to hours of administration.[1][2]
Steps in Suspected Allergy Diagnosis
Diagnosis starts with clinical history and exam:
- Patient history: Doctors review timing (e.g., during first or repeat infusion), prior reactions, and other drugs. Keytruda reactions often recur on re-challenge.
- Physical exam: Checks for hives, swelling, or vital sign changes like hypotension.
- Timing matters: Immediate (IgE-mediated) vs. delayed (T-cell mediated) helps differentiate true allergy from cytokine release syndrome, common early in treatment.[3]
No single lab test confirms Keytruda allergy definitively, as it's monoclonal antibody-specific.
Lab Tests and Confirmation Methods
- Tryptase levels: Blood test during reaction; elevated (>2x baseline) suggests mast cell activation in anaphylaxis-like events.[1]
- Skin testing: Rarely used due to risk. Intradermal tests with diluted Keytruda can provoke reactions but are avoided in cancer patients; graded challenge preferred.[4]
- Drug challenge: Gold standard for confirmation. Starts with small IV doses under monitoring (e.g., 10% of full dose, then full if tolerated). Done in hospital with epinephrine ready. Positive reaction (symptoms recur) confirms hypersensitivity.[2][5]
- Other labs: IgE levels, complement (C3/C4), or basophil activation tests are investigational and not routine for biologics like Keytruda.[3]
Differentiating from Other Reactions
| Reaction Type | Key Features | Diagnosis Clue |
|---------------|--------------|---------------|
| Infusion reaction | Fever, chills, flu-like within 1-4 hours | Resolves with slowing/stopping infusion; premeds like steroids help next time[1] |
| True allergy (hypersensitivity) | Hives, bronchospasm, repeat on low dose | Tryptase up; challenge confirms[2] |
| Immune-related (irAE) | Colitis, pneumonitis days-weeks later | Biopsy/endoscopy; not IgE-mediated[6] |
About 1-2% of Keytruda patients have severe hypersensitivity needing discontinuation.[7]
Management After Confirmation
Confirmed allergy leads to permanent Keytruda halt. Switch to alternatives like Opdivo (nivolumab) if cross-reactivity low (both PD-1 inhibitors but different antibodies).[4] Desensitization protocols exist for some biologics but are experimental for Keytruda, involving gradual re-exposure over hours.[5]
Sources
[1]: Keytruda Prescribing Information (Merck)
[2]: ASCO Guidelines on Hypersensitivity
[3]: J Allergy Clin Immunol on Monoclonal Antibodies
[4]: Ann Allergy Asthma Immunol Review
[5]: J Oncol Pract on Biologic Desensitization
[6]: NEJM Review on Immunotherapy Toxicities
[7]: FDA Adverse Event Reporting System (FAERS) Summary